Navigation Links
Viread in Medical News

Use Of Viread Spreads As New Anti-AIDS Site Is Launched

A website has been unveiled by the Los Angeles County health officials which will facilitate the sending of e-mails to keep people informed of HIV and other related diseases. The site called, inSPOTLA.org is meant // to check the spread of the diseases, and encourage safe sex. The site is targeted ...

FDA Approves New HIV Drug, Viread

Biopharmaceutical firm Gilead Sciences Inc. said it has received approval from the US Food and Drug Administration (FDA) to market its antiretroviral agent Viread (tenofovir disoproxil fumarate) for the treatment of HIV in combination with other antiretroviral agents. Like Viread, such drugs w...

Mylan Announces Tentative FDA Approval Under PEPFAR for Tenofovir Disoproxil Fumarate Tablets

...Disoproxil Fumarate Tablets, 300 mg. Matrix's Tenofovir Disoproxil Fumarate is the first and only generic tentative approval of Gilead Sciences Inc.'s viread Tablets, 300 mg. Matrix's ANDA was tentatively approved in less than six months and is the seventh PEPFAR tentative approval earned by Matrix within...

Gilead's AIDS Drug Awaits Patent in India

...ogramme and licensed Indian pharmas to manufacture viread which originally announced a pricing of $1 a day f...rant opposition against the patent application for viread before the patents office. But Alton said:...pla's right to oppose the issuance of a patent for viread or any drug. But more importantly, we reaffirm our...

Viread To Retail In India For $1

... The largest-selling HIV/AIDS drug, viread is to be made available in India at the special pr...ug. The Indian firms will make generic versions of viread and distribute it to 95 low-income countries aroun...much speculation in recent months with claims that viread had been overpriced, selling at $5,700 in the deve...

The New AIDS Pill

...on of drugs such as Sustiva, sold by Bristol-Myers Squibb, and Truvada, sold by Gilead Sciences. Truvada in turn is a combination of two Gilead drugs, viread and Emtriva. The FDA would approve the drug and then the drug would be available in the market. The companies said that the drug would cost the sa...

Drug Firms To Produce Single Pill AIDS Treatment

...ugs to be combined into a single pill are being marketed under the Emtriva, viread and Sustiva brand names separately as at present, and account for 20% of the AIDS drugs market. The combined viread and Emtriva medicines are already in the market under the name of Truvada. ...

Simplest therapeutic regimen found less effective against HIV

...-resistant strains of HIV. Therapeutic regimen that combines Videx and viread with so-called "non-nuke" drugs like Sustiva is one of several treatment gr...nt to the drugs when all three are used at once, possibly because Videx and viread attack the disease in a like-minded fashion, and so, the Department of Heal...
Viread in Medical Technology

Phase III Study Evaluating Gilead's Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint

FOSTER CITY, Calif.--(BUSINESS WIRE)--Jun 6, 2007 - Gilead Sciences, Inc. (Nasdaq:GILD) today announced that Study 102, a Phase III clinical trial evaluating the company's once-daily anti-HIV drug Viread (tenofovir disoproxil fumarate or tenofovir DF) 300 mg as a potential treatment for chronic hep...

Second Phase III Study Evaluating Gilead's Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint

FOSTER CITY, Calif.--(BUSINESS WIRE)--Jun 25, 2007 - Gilead Sciences, Inc. (Nasdaq:GILD) today announced that Study 103, a Phase III clinical trial evaluating the company's once-daily anti-HIV drug Viread(R) (tenofovir disoproxil fumarate or tenofovir DF) 300 mg as a potential treatment for chronic...

Second Phase III Study Evaluating Gilead's Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint

FOSTER CITY, Calif.--(BUSINESS WIRE)--June 25, 2007--Gilead Sciences, Inc. (Nasdaq:GILD) today announced that Study 103, a Phase III clinical trial evaluating the company's once-daily anti-HIV drug Viread(R) (tenofovir disoproxil fumarate or tenofovir DF) 300 mg as a potential treatment for chroni...

Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS)

... entitled "Risk Factors" and discussions of potential risks and uncertainties in our subsequent filings with the Securities and Exchange Commission. viread and Hepsera are registered trademarks of Gilead Sciences, Inc. ...

U.S. Patent Office Rejects Key HIV/AIDS Drug Patents at PUBPAT Request: Government Finds Prior Art Submitted By PUBPAT Invalidates All of Gilead Sciences' Claims

...ally as tenofovir disoproxil fumarate (TDF), a key weapon in the battle against HIV/AIDS. Gilead markets TDF in the United States under the brand name viread and as a part of its ATRIPLA combination product. Roughly 40 million people worldwide are infected with HIV/AIDS, including more than 1.2 million ...

European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection

...oproxil fumarate 300 mg), Emtriva (emtricitabine), viread (tenofovir disoproxil fumarate [DF]) and Truvada (...ve been reported in patients who have discontinued viread or Emtriva, which are components of Truvada and AT...complete U.S. prescribing information for Truvada, viread and Emtriva, including Boxed WARNINGS, visit http...

Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe

...proxil fumarate 300 mg), Emtriva (emtricitabine), viread (tenofovir disoproxil fumarate [DF]) and Truvada ...ve been reported in patients who have discontinued viread or Emtriva, which are components of Truvada and AT...complete U.S. prescribing information for Truvada, viread and Emtriva, including Boxed WARNINGS, visit http...

European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg)

...oproxil fumarate 300 mg), Emtriva (emtricitabine), viread (tenofovir disoproxil fumarate [DF]) and Truvada (...ve been reported in patients who have discontinued viread or Emtriva, which are components of Truvada and AT... . Full U.S. prescribing information for Truvada, viread and Emtriva are available at...

Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV

...oproxil fumarate 300 mg), Emtriva (emtricitabine), viread (tenofovir disoproxil fumarate [DF]) and Truvada (...ve been reported in patients who have discontinued viread or Emtriva, which are components of Truvada and AT... For complete prescribing information for Truvada, viread and Emtriva, visit http://www.gilead.com . About...
Viread in Biological News

Anti-HIV drug has potential to prevent transmission in women

... tenofovir produced mild or no side effects in both HIV positive and HIV negative women. Tenofovir is the active ingredient in the antiretroviral drug viread made by Gilead Sciences. Currently, there is no microbicide available that has been approved for widespread use. The tenofovir study was a safety a...
Other Tags
(Date:9/1/2015)... ... September 01, 2015 , ... OncLive® today announced ... News & World Report, to provide breaking news and information about the hospital’s ... within OncLive, which provides oncologists resources and information?they need to deliver the best ...
(Date:9/1/2015)... ... September 01, 2015 , ... PetPace, the provider of an ... and activity, today announced its integration with leading veterinary Practice Management Software vendor ... hospital Practice Management Software packages in the US. Practice Management Software helps veterinarians ...
(Date:9/1/2015)... ... 2015 , ... e-Spirit Inc., a leading supplier of content ... Management System with new capabilities and enhancements designed to support the recently announced ... well on their way to achieving digital transformation with less time and less ...
(Date:9/1/2015)... ... 01, 2015 , ... WorkCare, Inc., a national occupational health ... team as an Associate Medical Director. , WorkCare specializes in workforce health ... and abroad. , Dr. Nelson has a diverse background. He trained in ...
(Date:9/1/2015)... Diego, CA (PRWEB) , ... September 01, 2015 , ... ... are just a few of the topics to be discussed at Seedstock’s 4th Annual ... Nov. 3-4, 2015, at UC San Diego. , In addition to keynotes Pierre ...
Breaking Medicine News(10 mins):Health News:OncLive® and Cleveland Clinic Team up to Provide News, Information About Cancer Research and Patient Care 2Health News:OncLive® and Cleveland Clinic Team up to Provide News, Information About Cancer Research and Patient Care 3Health News:Petpace-Cornerstone Integration Lowers Overhead, Raises Data Visibility for Veterinary Practices 2Health News:e-Spirit boosts Corporate Content Cloud initiative with release of FirstSpirit 5.2 2Health News:e-Spirit boosts Corporate Content Cloud initiative with release of FirstSpirit 5.2 3Health News:Dr. Brent Nelson Joins WorkCare, Inc., as Associate Medical Director 2Health News:Dr. Brent Nelson Joins WorkCare, Inc., as Associate Medical Director 3Health News:Experts in Urban and Local Food Systems Development to Address Seedstock Sustainable Agriculture Conference Nov. 3-4 Discounted ticket sales end Sept. 4 2Health News:Experts in Urban and Local Food Systems Development to Address Seedstock Sustainable Agriculture Conference Nov. 3-4 Discounted ticket sales end Sept. 4 3Health News:Experts in Urban and Local Food Systems Development to Address Seedstock Sustainable Agriculture Conference Nov. 3-4 Discounted ticket sales end Sept. 4 4Health News:Experts in Urban and Local Food Systems Development to Address Seedstock Sustainable Agriculture Conference Nov. 3-4 Discounted ticket sales end Sept. 4 5
(Date:8/25/2015)... BELLEVUE, Wash. , Aug. 25, 2015  Sarcos ... today it will unveil its "Guardian S" snake robot, ... National Tactical Officers Association Conference on August 30 in ... is the first-ever commercially available energetically autonomous snake robot, ... in-field trials and is protected by more than 50 ...
(Date:8/20/2015)... 20, 2015 The wearable technology market ... active and healthy. However, wearable technology has the ... to help improve diagnostic capabilities and therapeutic outcomes. ... Wearable Technologies Conference 2015 , where ... wearables in healthcare.    "Over the ...
(Date:8/19/2015)... N.Y. , Aug. 19, 2015  VOXX ... that it has entered into a Definitive Agreement ... property, of iris authentication market leader EyeLock through ... VOXX will have a controlling interest in the ... subject to completion of due diligence.  Expanding on ...
Breaking Biology News(10 mins):Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5
Other Contents